Related Experiment Video

Updated: May 21, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Effects of allopurinol on coronary microvascular and left ventricular function in patients with idiopathic dilated

Dogan Erdogan1, Senol Tayyar, Bayram Ali Uysal

  • 1Suleyman Demirel University, Faculty of Medicine, Cardiology Department, Isparta, Turkey. aydoganer@yahoo.com

The Canadian Journal of Cardiology
|June 22, 2012
PubMed

Insights

Allopurinol treatment significantly reduced uric acid (UA) levels in patients with idiopathic dilated cardiomyopathy (IDC). This led to marked improvements in left ventricular (LV) function and coronary flow reserve (CFR).

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Elevated uric acid (UA) is linked to mortality and oxidative stress in heart failure.
  • Idiopathic dilated cardiomyopathy (IDC) patients with high UA may have impaired cardiac function.

Purpose of the Study:

  • To evaluate allopurinol's effect on left ventricular (LV) function and coronary microvascular integrity in IDC patients.
  • To assess the impact of reducing UA levels on cardiac parameters.

Main Methods:

  • 39 IDC patients were grouped by UA levels: elevated (>7 mg/dL men, >6.5 mg/dL women) and normal.
  • The elevated UA group received allopurinol (300 mg/day) for 3 months.
  • Echocardiography assessed LV function (systolic/diastolic) and coronary flow reserve (CFR).

Main Results:

  • Elevated UA group had lower LV ejection fraction and impaired CFR, diastolic, and combined LV functions.
  • Allopurinol treatment significantly decreased UA levels and markedly improved CFR.
  • UA reduction correlated directly with CFR improvement; LV diastolic and systolic parameters improved.

Conclusions:

  • Allopurinol effectively reduces UA levels in IDC patients with hyperuricemia.
  • A 3-month allopurinol regimen improves LV function and CFR in these patients.
  • Targeting UA with allopurinol is a potential therapeutic strategy for IDC.
Abstract

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...